Annovis Bio ANVS

Annovis Bio, Inc. is a late stage clinical drug platform company focused on neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease. The company’s lead candidate, buntanetap, is an orally administered small molecule designed to inhibit the translation of several neurotoxic proteins, including amyloid precursor protein, tau, alpha synuclein and TDP 43, with the goal of restoring axonal transport and reducing neuronal death. Annovis is conducting pivotal clinical trials for buntanetap in early Alzheimer’s disease and has an open label study in Parkinson’s disease, while also advancing programs for acute brain trauma and later stage Alzheimer’s.

Annovis Bio, Inc. has not yet commercialized a product and therefore does not generate product sales revenue. The company finances its research and development activities primarily through grant funding, including a previously awarded grant from the U. S. Army for its acute trauma program, and through capital raising efforts such as public and private equity offerings. These funds support ongoing clinical trials, manufacturing arrangements with third‑party contractors, and general corporate operations.

Annovis Bio, Inc. occupies a differentiated position in the neurodegenerative disease market by targeting multiple pathogenic proteins with a single oral small molecule, whereas many competitors focus on single target approaches such as anti amyloid monoclonal antibodies or anti tau therapies. Key competitors in Alzheimer’s disease include Eisai with lecanemab, Biogen with aducanumab, and Eli Lilly with donanemab, while in Parkinson’s disease the standard of care remains levodopa based therapies and emerging disease modifying agents such as exenatide. Annovis believes its mechanism, which reduces translation of amyloid, tau, alpha synuclein and TDP 43, offers a potential disease modifying advantage that addresses the underlying pathology rather than merely symptomatic relief.

Annovis Bio, Inc. intends to serve patients diagnosed with Alzheimer’s disease, Parkinson’s disease and related neurodegenerative conditions. Upon regulatory approval, the company plans to sell its therapies to neurologists, geriatric specialists and primary care physicians who treat these patient populations. No specific customer names are disclosed in the filing.